Literature DB >> 2861834

Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.

A O Molajo, D H Bennett.   

Abstract

The effect of xamoterol, a beta1 adrenoceptor partial agonist, on resting haemodynamic measurements and exercise tolerance was studied in 10 patients with dyspnoea of effort. All patients had poor left ventricular function due to myocardial infarction with ejection fractions ranging from 15% to 35% (mean 28%). The cardiac index and stroke work index both rose significantly. The mean pulmonary artery pressure fell from 20(2) mm Hg to 16(2) mm Hg and pulmonary artery wedge pressure from 14(2) mm Hg to 10(2) mm Hg within the first four hours. Exercise tolerance, measured on the treadmill, increased significantly in seven patients but was unchanged in the three who had the lowest left ventricular ejection fractions. Exercise heart rate response was attenuated by the drug in all patients. It is concluded that xamoterol may be beneficial in patients with poor left ventricular function but can be harmful in extremely poor left ventricular function where high sympathetic drive may be important.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861834      PMCID: PMC481841          DOI: 10.1136/hrt.54.1.17

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  6 in total

Review 1.  Exercise stress testing in evaluation of patients with ischemic heart disease.

Authors:  R A Bruce; T R Hornsten
Journal:  Prog Cardiovasc Dis       Date:  1969-03       Impact factor: 8.194

2.  Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitalised patients with chronic atrial fibrillation.

Authors:  A O Molajo; M O Coupe; D H Bennett
Journal:  Br Heart J       Date:  1984-10

3.  The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist.

Authors:  A Nuttall; H M Snow
Journal:  Br J Pharmacol       Date:  1982-10       Impact factor: 8.739

Review 4.  Neurohumoral control mechanisms in congestive heart failure.

Authors:  J N Cohn; T B Levine; G S Francis; S Goldsmith
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

5.  Beta-adrenoceptor stimulant properties of amidoalkylamino-substituted 1-aryl-2-ethanols and 1-(aryloxy)-2-propanols.

Authors:  J J Barlow; B G Main; H M Snow
Journal:  J Med Chem       Date:  1981-03       Impact factor: 7.446

6.  Effects of a cardioselective beta 1 partial agonist (corwin) on left ventricular function and myocardial metabolism in patients with previous myocardial infarction.

Authors:  M F Rousseau; H Pouleur; M F Vincent
Journal:  Am J Cardiol       Date:  1983-05-01       Impact factor: 2.778

  6 in total
  14 in total

1.  Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.

Authors:  E Vigholt-Sørensen; O Faergeman
Journal:  Br Heart J       Date:  1990-09

Review 2.  Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?

Authors:  D G Waller
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

3.  Pharmacokinetics of xamoterol after intravenous and oral administration to patients with chronic heart failure.

Authors:  E V Sorensen; O Faergeman; M Day; W Bastain
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  R Furlong; R N Brogden
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 5.  Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.

Authors:  H F Marlow
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

6.  Digoxin and xamoterol in patients with moderate chronic heart failure. A double-blind, randomized, controlled study.

Authors:  E V Sorensen; B Sterndorff; M F Andersen; O Faergeman
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

7.  Effects of xamoterol on resting and exercise haemodynamics in patients with chronic heart failure.

Authors:  S J Virk; M K Davies
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

8.  Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.

Authors:  E Vigholt-Sørensen; O Faergeman; H M Snow
Journal:  Br Heart J       Date:  1989-11

9.  The effects and dose-response relationship of xamoterol in patients with ischaemic heart disease.

Authors:  A O Molajo; D H Bennett; H F Marlow; H M Snow; W Bastain
Journal:  Br J Clin Pharmacol       Date:  1987-09       Impact factor: 4.335

10.  Cardiovascular actions of OPC-18790: a novel positive inotropic agent with little chronotropic action.

Authors:  T Hosokawa; T Mori; H Fujiki; S Kinoshita; K Takemoto; T Imaizumi; T Noda; M Ohura; M Tominaga; Y Yabuuchi
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.